At what enterprise value was LABORATOIRE POLIDIS acquired in 2025?

You can find the full valuation details of LABORATOIRE POLIDIS on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LABORATOIRE POLIDIS when it was acquired by SIPAREX?

The exact EV/EBITDA multiple for LABORATOIRE POLIDIS is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was LABORATOIRE POLIDIS acquired by SIPAREX?

LABORATOIRE POLIDIS was acquired by SIPAREX in 2025.

What was the revenue of LABORATOIRE POLIDIS at the time of the deal?

The revenue of LABORATOIRE POLIDIS at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LABORATOIRE POLIDIS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORATOIRE POLIDIS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.siparex.com/wp-content/uploads/2025/03/CP_LaboratoirePolidis-04.03.25.pdf

← DATABASE

Home Database Healthcare & PharmaLABORATOIRE POLIDIS

03/2025

LABORATOIRE POLIDIS acquired by SIPAREX

FRANCE Life Sciences / Medical Devices / Medical Consumables REV 5M - 25M EUR

Context

Laboratoire Polidis has completed its first-ever capital opening. Siparex Entrepreneurs and UI Investissement have joined the company as minority shareholders to support its next growth phase and formalize a new managerial transition.

LABORATOIRE POLIDIS, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Laboratoire Polidis is a leading French manufacturer and distributor of high-quality medical devices and consumer health products. Founded in 1986 and headquartered in Rueil-Malmaison, the company has built a strong industrial reputation by specializing in essential pharmaceutical products that combine technical efficacy with public accessibility. Its business model is centered on being a "trusted partner" to the pharmacy sector, with its products currently found in approximately one out of every three pharmacies in France.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Implants & Prosthetics
03/2025	LBO FRANCE	HEMODIA	FRANCE	Medical Devices
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Animal Health
02/2025	EURAZEO / TURENNE CAPITAL / KURMA PARTNERS	GERMITEC	FRANCE	Medical Devices
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Diagnostic Equipment
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Medical Consumables

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORATOIRE POLIDIS by SIPAREX are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: laboratoire polidis

Acquirer: siparex